Miguel Pinto
| Using a nanomedicine-based approach as a second chance for tolcapone |
| Pinto Miguel1, Fernandes Carlos1, Machado Cláudia1, Sarmento Bruno2, Remião Fernando3, Otero-Espinar Francisco4 and Borges Fernanda5 1 RISE-Health, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal; 2 Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; 3 Associate Laboratory i4HB – Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050‐13 Porto, Portugal; 4 Pharmacology, Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy and Institute of Materials (iMATUS), University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; 5 RISE-Health, Faculty of Sciences, University of Porto, Rua do Campo Alegre s/n, 4169-007, Porto, Portugal. |
| Abstract |
| References [1] Funding |